organised data on eli lilly

8/2/2019 Organised Data on Eli Lilly

1/17


2/17


3/17

Lilly and the Rest

Rank 04 [03 Rank] Company & Headquarte 2004 Global Sales ($bil

Pfizer

1[1] New York, NY 46.133

GlaxoSmithKline

2[2] London, England 31.377

Sanofi-Aventis

3[17/5] Paris, France 30.919

Johnson & Johnson

4[4] New Brunswick, NJ 22.128

Merck

5[3] Whitehouse Station, NJ 21.493

Lilly

11[10] Indianapolis, IN 13.059

Roche

15[16] Osaka, Japan 8.274


4/17

Change from 2003

R&D Expenses

(in $billions) 2004 Top Selling Drugs

R&D to

Sales

Ratio%

Lilly and The rest

Lipitor $10.862 billionNorvasc $4.463 billion

6% 7.52 Zoloft $3.361 billion 16.30

Seretide/Advair $4.503 billion

Avandia $2.042 billion

5% 5.195 Seroxat/Paxil $1.945 billion 16.56

Lovenox $2.38 billion

Plavix $2.17 billion

12% 9.31 Allegra $1.87 billionProcrit/Eprex $3.589 billion

Risperdal $3.050 billion

13% 5.203 Remicade $2.145 billion 23.51

Zocor $5.2 billion

Fosamax $3.2 billion

-4% 4.01 Cozaar/Hyzaar $2.8 billion

Nexium $3.8 billion

Seroquel $2.02 billion

4% 2.69 Zyprexa $4.4 billion 20.60

12% 1.223 Actos $1.676 billion 14.78


5/17

Ranking of Companies according to stage of Alliance Deals

company Early Stage Clinical Advanced

Abbot labs 9 13 1

Amgen 1 14 14

Astra Zeneca 6 12 6

Beohringer Ingelhelm 15 1 3

Bristol-Myers Squibb 13 7 2GlaxoSmithKline 10 2 13

J&J 4 11 12

Lilly 12 5 5

Merck 2 15 7

Novaratis 3 6 15

Pfizer 7 10 9

Roche 11 4 10

Sanofi-Aventis 8 8 8

Takeda 14 3 4

Wyeth 5 9 11

disribution of alliance deals by stages

proportion

company early stage clinical advanced clinical

Takeda 28% 43% 28%

Beohringer Ing 22% 47% 31%

Amgen 81% 9% 9%

Roche 38% 42% 20%

Lilly 35% 37% 28%Abbot labs 44% 15% 41%

Wyeth 49% 33% 18%

Bristol-Myers 32% 34% 35%

Novaratis 58% 37% 5%

Astra Zeneca 47% 27% 25%

Merck 76% 1% 23%

J&J 58% 28% 14%

Sanofi-Aventis 45% 33% 22%

GlaxoSmithKli 41% 46% 13%

Pfizer 46% 32% 22%


6/17

Ranking of Companies according to stage of Alliance Deals

RANK ACCORDING TO % of Inlicencing

Rank Company

1 Takeda

2 Bristol-Myers Squibb

3 Hoffmann-La Roche

4 Pfizer

5 Abbott6 Novartis

7 Schering AG

8 Chiron

9 Johnson & Johnson

10 Lilly

11 Sankyo

12 Akzo Nobel

13 GlaxoSmithKline

14 Merck & Co.

15 Genzyme

16 Sanofi-Aventis17 Wyeth

18 Amgen

19 AstraZeneca

20 Lexicon Genetics

0

2

4

6

8

10

12

14

16 Early Stage

Clinical

Advanced


7/17


8/17

IN-LICENSING OF DRUGS BY LARGE PHARMA

Total R&D Own Drugs In-Licensing

In Licencing as

Percentage of Total

1 Sanofi-Aventis 221 151 70 31.67

2 GlaxoSmithKline 172 105 67 38.95

3 Hoffmann-La Roche 140 72 68 48.57

4 Johnson & Johnson 117 68 49 41.88

5 Merck & Co. 112 71 41 36.61

6 Pfizer 112 61 51 45.54

7 Novartis 110 61 49 44.55

8 AstraZeneca 104 80 24 23.08

9 Wyeth 90 62 28 31.11

10 Bristol-Myers Squibb 82 38 44 53.6611 Lilly 75 45 30 40.00

12 Abbott 66 36 30 45.45

13 Schering AG 61 35 26 42.62

14 Genzyme 56 37 19 33.93

15 Lexicon Genetics 49 49 0 0.00

16 Sankyo 48 29 19 39.58

17 Takeda 47 21 26 55.32

18 Chiron 45 26 19 42.22

19 Amgen 45 33 12 26.67

20 Akzo Nobel 43 16 17 39.53

Notes: Total R&D Drugs refers to the total number of active Research and Developme

suspended products), as of February 2005.

Own Drugs refers to the number of drugs originating from each companys own resear

In-Licensing refers to the number of drugs each company has licensed-in.

Source: http://www.pharmaprojects.com, accessed October 11, 2005.


9/17

Rank Company

In Licencing as

Percentage of

Total

1 Takeda 55.32

2 Bristol-Myers Squibb 53.66

3 Hoffmann-La Roche 48.57

4 Pfizer 45.54

5 Abbott 45.45

6 Novartis 44.55

7 Schering AG 42.62

8 Chiron 42.22

9 Johnson & Johnson 41.88

10 Lilly 40.00

11 Sankyo 39.5812 Akzo Nobel 39.53

13 GlaxoSmithKline 38.95

14 Merck & Co. 36.61

15 Genzyme 33.93

16 Sanofi-Aventis 31.67

17 Wyeth 31.11

18 Amgen 26.67

19 AstraZeneca 23.08

20 Lexicon Genetics 0.00

t (R&D) projects (excluding

ch.


10/17

LILLY FINANCIALS, 20002004

(in US$ million)2000 2001 2002 2003 2004

Net sales 10,862 11,542 11,077 12,582 13,859

Foreign sales 3,858 4,178 4,495 5,361 6,189Research and development ex 2,019 2,235 2,149 2,350 2,691

Income from continuing oper 3,859 3,507 3,458 3,261 2,941

Net income 3,058 2,780 2,707 2,561 1,810

Year end share price1 93.6 78.54 63.5 70.33 56.75

Market capitalization 66,709 86,599 89,348 63,970 64.53

Dividends per share 1 1.06 1.12 1.24 1.36 1.45

Current assets 7,943 6,939 7,804 8,769 12,836

Current liabilities 4,961 5,203 5,063 5,561 7,594

Property and equipment 4,177 4,532 5,293 6,539 7,551

Total assets 14,691 16,434 19,042 21,688 24,867

Long-term debt 2,634 3,132 4,358 4,688 4,492

Shareholder equity 6,047 7,104 8,274 9,765 10,920

Number of employees 35,700 41,100 43,700 45,000 44,500

1Share price and dividend per share are in US$.

Source: Company Annual Reports.

Market value and share prices sourced from Forbes.com.


11/17


12/17


13/17


14/17

How do we link exhibit 9 and 10?

How does it help us to look at the experience with alpha, beta and g


15/17

mma


16/17


17/17

Can we view the dimensions as critical success factors in making an alliance succeed

What do you see as the purpose of the Spider diagram?

Can we use this for evaluating the experience with alpha, beta and gamma?

organised data on eli lilly

Documents